Unusual Mucopolysaccharidoses cases. Tim Hutchin and Louise Allen Newborn Screening and Biochemical Genetics, Birmingham Children s Hospital

Similar documents
Quantitation and Identification of Urine Mucopolysaccharides. George Gray MetBioNet Workshop 2008

Mucopolysaccharidoses diagnostic approaches

A Rare disease: MPS III San Filippo disease

Disclosures. Learning Objectives. Inheritance patterns. Lysosomal function. Mucopolysaccharidoses (MPS): Keys to Early Recognition and Intervention

Clinical Approach to Diagnosis of Lysosomal Storage Diseases

Inborn Error Of Metabolism :

International Journal of Current Research in Sciences

Date of commencement: February Principal Investigator Dr. Jayesh J. Sheth CASE RECORD FORM

THE EFFECTS OF UNDEGRADED GLYCOSAMINOGLYCANS FROM MUCOPOLYSACCHARIDOSES ON OSTEOBLAST DIFFERENTIATION AND MINERALISATION IN VITRO

Abstract. Malaysian J Pathol 2010; 32(1) : 35 42

Chairman: DR B. D. CORNER

7 Medical Genetics. Hemoglobinopathies. Hemoglobinopathies. Protein and Gene Structure. and Biochemical Genetics

INBORN ERRORS OF METABOLISM (IEM) IAP UG Teaching slides

Update on the management of neurometabolic disorders in children.

was normal and by age 14 months she was walking alone. Compared with her brothers her speech development was delayed, with first words

original article Egypt. J. Med. Hum. Genet. Vol. 9, No. 1, May 2008

What s New in Newborn Screening?

C3, C4, C5, C6 2. & C7

Lysosomal Storage Disorders. Karen Fieggen UCT Human Genetics Groote Schuur Hospital

Summary. Syndromic versus Etiologic. Definitions. Why does it matter? ASD=autism

Hepatomegaly: A Major Clinical Sign in Some Metabolic Disorders

The role of the laboratory in diagnosing lysosomal disorders

Most mammalian cells are located in tissues where they are surrounded by a complex extracellular matrix (ECM) often referred to as connective tissue.

Family Medical History Questionnaire (FMHQ)

The Diagnosis of Morquio Disease Correlating the Clinical, Radiological and Biochemical Findings: A Case Series

Glossary. A resource for individuals and families living with MPS. apneic episodes: Periods of time where breathing stops.

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

What s New in Newborn Screening?

Hurler Syndrome (Severe Type) -A Rare Case Report

Corporate Medical Policy. Policy Effective 6/30/2017

Overview of the mucopolysaccharidoses

The mucopolysaccharidoses: a clinical review and guide to management

Newcastle University eprints

Early Diagnosis of the Mucopolysaccharidoses (MPS): An Orthopedic Perspective. Disclosures

Clinical features of Mexican patients with Mucopolysaccharidosis type I

Gene Expression-Targeted Isoflavone Therapy: Facts, Questions and Further Possibilities

UvA-DARE (Digital Academic Repository) Improving the diagnosis and treatment of MPS I Langereis, E.J. Link to publication

JMSCR Vol 06 Issue 06 Page June 2018

Diagnostic Proficiency Testing Survey Annual Report

Mucopolysaccharidoses: early diagnostic signs in infants and children

OPHTHALMOLOGICAL FINDINGS IN A PATIENT WITH MUCOLIPIDOSIS III (PSEUDO- HURLER POLYDYSTROPHY). A CASE REPORT.

Urinary excretion of glycosaminoglycans in the

Section 2: Multivariate or Multiple Domain Methods Aldurazyme Responder Index

Childhood Onset of Scheie Syndrome, the Attenuated Form of Mucopolysaccharidosis I

Proficiency Testing Centre Prague Annual Report 2011

Lipids: In Born errors of Metabolism I

From hypertransaminasemia to mucopolysaccharidosis IIIA

1. Diagnosis of Lysosomal Storage Disorders in Australia. 2. Comparison of Incidence/prevalence of lysosomal storage diseases in different country

Corporate Medical Policy. Policy Effective October 9, 2018

Canadian Consensus Position Statement for the Diagnosis and Management of MPS II

SACCHARIDOSES 7.2 MUCOPOLY. Frances Dougherty Kendall and Gemld Cox REFERENCES

Causal Therapies in Mucopolysaccharidoses: Enzyme Replacement Therapy

Obstructive Sleep Apnea in MPS: A Systematic Review of Pretreatment and Posttreatment Prevalence and Severity

Chapter 126 Impairment of Body Growth in Mucopolysaccharidoses

Evaluation of disease severity in mucopolysaccharidoses

Chapter-6. Discussion

Disorder name: Severe Combined Immunodeficiency Acronym: SCID

Carpal Tunnel Syndrome in Pediatric Mucopolysaccharidoses

Treatment of Hurler MPSI with a Blood-Brain Barrier Penetrating IgG-Lysosomal Enzyme Fusion Protein

ANNUAL REPORT In 2005 the DPT centre Central Europe had 21 participants from Germany, The Netherlands, Belgium and the United Kingdom.

Natural history of Sanfilippo syndrome type A

Whole-exome sequencing expands the phenotype of Hunter syndrome

A RARE CASE REPORT: MUCOPOLY-SACCHARIDOSIS (HURLER SYNDROME) WITH RACHITIC CHANGES IN A NIGERIAN

Assay Kit for Measurement of Proteoglycan. (Sulfated Glycosaminoglycan Quantification Kit)

Structure. Lysosomes are membrane-enclosed organelles. Hydrolytic enzymes. Variable in size & shape need

BRAIN STEM CASE HISTORIES CASE HISTORY VII

Anthropometric characteristics of four Polish children with mucopolysaccharidosis

Texas Prior Authorization Program Clinical Criteria

Establishment of Glycosaminoglycan Assays for Mucopolysaccharidoses

Klinefelter syndrome ( 47, XXY )

Genetic Disorders. n A genetic disorder is an abnormality

Case Report Morquio s Syndrome: A Case Report of Two Siblings

Assessment of bone dysplasia by micro-ctand glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII

A Guide to Understanding Maroteaux-Lamy Disease (MPS VI)

Enzyme Replacement Therapy for Lysosomal Storage Diseases

The Patient Perspective: diagnostic Exome Sequencing

Diagnostic Test for Mucopolysaccharidosis. II. Rapid Quantificationof Glycosaminoglycan in Urine Samples Collected on a Paper Matrix

Guidelines for the Investigation and Management of Mucopolysaccharidosis type VI

and Kevin Mills 1.* WC1N 3JH, UK 9700 RB Groningen, Netherlands.

Joseph Muenzer, M.D., Ph.D. University of North Carolina at Chapel Hill Chapel Hill, NC, USA. February 7 th, Orlando, FL

STRIDE PLUS STRIDE PLUS. Nutritional Maintenance of Healthy Cartilage and Joints in Dogs. 100%

HEREDITARY METABOLIC DISEASES

ERNDIM Urine mucopolysaccharides ANNUAL REPORT 2018

RMP version 3.0 Aripiprazole

Standard Therapies - Cord Blood

Gary Autism s/s age c98

Fatty Acid Oxidation Disorders

Gary Autism s/s age 0-7

CENTRAL CARE POLICY SYMPTOMS OF ILLNESS. Policy: Consumers will be observed for symptoms of physical problems, distress, pain, or unusual behaviors.

ERNDIM Urine mucopolysaccharides ANNUAL REPORT 2017

Parent 1/Guardian Information. Parent 1/Guardian Information (If Different from Above)

History Taking 3rd year Lecture. Thembi Katangwe 1st March 2011

Hearing Loss and Autism. diagnosis and intervention

Prior Authorization Review Panel MCO Policy Submission

Neonatal manifestations of lysosomal storage diseases

Laronidase for treating mucopolysaccharidosis type I

Sanfilippo disease (mucopolysaccharidosis type III): Early diagnosis and treatment de Ruijter, J.

Autism and other developmental disorders. Dr. Martin Maldonado

PedsCases Podcast Scripts

Transcription:

Unusual Mucopolysaccharidoses cases Tim Hutchin and Louise Allen Newborn Screening and Biochemical Genetics, Birmingham Children s Hospital

A Brief MPS History Lesson.. In 1917 Hunter (type II) reported two brothers with coarse facial features, mental retardation and bone disorders. First detailed description of an MPS was Hurler (Type I) in 1919. In 1929 Morquio gave a precise description of MPS IV and 1963 Sanfilippo defined Type III. Why no MPS V? In 1962 Scheie and colleagues described a patient with corneal clouding and skeletal dysplasia initially referred to as MPS V until it was discovered that it was a milder form of Type I. 1963 Dr Maroteaux and Dr Lamy (MPS VI) 1972 Dr William Sly (MPS VII) 1996 Natowicz (MPS IX) -Hyaluronidase deficiency (one case?)

Signs and symptoms of MPS can be difficult to identify as they may overlap with common childhood complaints. Early diagnosis is important as treatment options are available for some. Clinically heterogeneous but generally characterized by a period of normal growth and development, followed by progressive organomegaly, developmental delay, skeletal abnormalities, cardiac abnormalities, coarsening of facial features. Hearing loss, corneal clouding, joint stiffness and short stature may occur. Mental retardation occurs in some forms. Diagnosis is made by increased excretion of glycosaminoglycans (GAGs) in urine and then determination of the GAG(s) excreted by 1D and/or 2D electrophoresis. Confirmation by enzyme or DNA analysis.

One Dimensional Cellulose Acetate Electrophoresis

Case 1- Difficulties making a diagnosis 2 year old boy Global developmental delay Mild dysmorphic features Plagiocephaly (flat head) Hepatomegaly and nephromegaly Dysplastic hips Unusual rocking behaviour Severe speech delay

1 st urine- raised DMB 61.8mg/mmol creatine (<37.6) 1D too faint organic acids unsatisfactory possibly due to interfering substance urine also dilute Pos QC 2 nd urine- raised DMB (47 mg/mmol) but 1D too faint again organic acids suggested presence of contaminating emollient/soap

3 rd urine- raised DMB - 46.9 mg/mmol 1D and 2D showed spots in position of heparan and heparin-like component organic acids did not show contaminating bands Heparan sulphate Chondroitin sulphate Pos QC Enzyme analysis confirmed MPS IIIA. No treatment currently available

Case 2 - Difficulties not making a diagnosis 3 year old girl Skull asymmetry Developmental delay Out of region patient with raised DMB

1 st urine- raised DMB 45.1mg/mmol creatine (<37.6) 2D showed a spot of unknown significance Unknown spot Chondroitin sulphate Heparan sulphate

2 nd & 3 rd urine- raised DMB 8.0 & 7.5 mg/mmol creatine (<37.6) 1D electrophoresis normal So not consistent with an MPS disorder

Case 3- Diagnosis via Media

Case 3- Diagnosis via Media 2 year old boy, previously seen for sepsis/ jaundice and persistent wheeze. In and out of hospital with persistent infections. Large head. Seen in outpatients where mother told doctor he has what that little boy on television has and asked Dr to take a sample to test for this. Channel 4 series Inside Birmingham Children s Hospital had recently featured brothers with MPS II (Hunters).

Urine showed increased DMB (94.5mg/mmol), heavy band of dermatan and subsequent enzyme analysis confirmed diagnosis of MPSII Pos QC Child is now 4 years old and on ERT. Attending nursery though has problems with delayed motor skills, can be aggressive, development is levelling off.

Confusion via Media The dad who thought his son s MPS3B had been caused by being bitten by a schipperke dog somewhere in the forests of Eastern Europe where the family originates from. Sugar consumption reduced as a potential treatment

Unclear/incomplete Request Forms Positive nitrite - patient actually had developmental delay (MPS3) Mosquito syndrome Technical problems Difficulties with Urine GAGs Urine too dilute or contaminated, e.g. heparin in patients on ITU or cardiac patients, emollients in nappy (or beauty) creams. No cellulose acetate!!! The Future MS/MS methods Newborn Screening for MPS